+

WO2003039598A8 - Inhibiteurs selectif de recaptage de la norepinephrine et de la serotonine utilises dans le traitement du syndrome de la fibromyosite, de l'encephalo-myelite myalgique et de la douleur - Google Patents

Inhibiteurs selectif de recaptage de la norepinephrine et de la serotonine utilises dans le traitement du syndrome de la fibromyosite, de l'encephalo-myelite myalgique et de la douleur

Info

Publication number
WO2003039598A8
WO2003039598A8 PCT/US2002/035396 US0235396W WO03039598A8 WO 2003039598 A8 WO2003039598 A8 WO 2003039598A8 US 0235396 W US0235396 W US 0235396W WO 03039598 A8 WO03039598 A8 WO 03039598A8
Authority
WO
WIPO (PCT)
Prior art keywords
syndrome
pain
serotonin reuptake
reuptake inhibitors
selective norepinephrine
Prior art date
Application number
PCT/US2002/035396
Other languages
English (en)
Other versions
WO2003039598A1 (fr
Inventor
Srinivas G Rao
Jay D Kranzler
Original Assignee
Cypress Bioscience Inc
Srinivas G Rao
Jay D Kranzler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cypress Bioscience Inc, Srinivas G Rao, Jay D Kranzler filed Critical Cypress Bioscience Inc
Priority to ES02793880T priority Critical patent/ES2395462T3/es
Priority to EP02793880A priority patent/EP1463528B1/fr
Priority to AT02793880T priority patent/ATE552856T1/de
Priority to CA002467356A priority patent/CA2467356C/fr
Publication of WO2003039598A1 publication Critical patent/WO2003039598A1/fr
Publication of WO2003039598A8 publication Critical patent/WO2003039598A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

la présente invention concerne une méthode de traitement, chez un mammifère, de l'encéphalo-myélite myalgique, de l'encéphalo-myélite myalgique associée à la dépression, d'une combinaison d'encéphalo-myélite myalgique et du syndrome de la fibromyosite, du syndrome de la fibromyosite associé à la dépression, de la douleur et de la douleur associée à la dépression. La méthode consiste à administrer une dose thérapeutiquement efficace d'un composé inhibiteur double de recaptage de la sérotonine et de la norépinéphrine ou un sel de ce composé acceptable au plan pharmaceutique.
PCT/US2002/035396 2001-11-05 2002-11-05 Inhibiteurs selectif de recaptage de la norepinephrine et de la serotonine utilises dans le traitement du syndrome de la fibromyosite, de l'encephalo-myelite myalgique et de la douleur WO2003039598A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES02793880T ES2395462T3 (es) 2001-11-05 2002-11-05 Inhibidores selectivos de la recaptación de norepinefrina-serotonina para el tratamiento del síndrome de fibromialgia, síndrome de fatiga crónica y dolor
EP02793880A EP1463528B1 (fr) 2001-11-05 2002-11-05 Inhibiteurs selectif de recaptage de la norepinephrine et de la serotonine utilises dans le traitement du syndrome de la fibromyosite, de l'encephalo-myelite myalgique et de la douleur
AT02793880T ATE552856T1 (de) 2001-11-05 2002-11-05 Selektive norepinephrin-serotonin- wiederaufnahmehemmer zur behandlung des fibromyalgie-syndroms, des chronischen müdigkeitssyndroms und von schmerzen
CA002467356A CA2467356C (fr) 2001-11-05 2002-11-05 Inhibiteurs selectif de recaptage de la norepinephrine et de la serotonine utilises dans le traitement du syndrome de la fibromyosite, de l'encephalo-myelite myalgique et de la douleur

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/014,149 US6635675B2 (en) 2001-11-05 2001-11-05 Method of treating chronic fatigue syndrome
US10/014,149 2001-11-05

Publications (2)

Publication Number Publication Date
WO2003039598A1 WO2003039598A1 (fr) 2003-05-15
WO2003039598A8 true WO2003039598A8 (fr) 2004-06-03

Family

ID=21763814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035396 WO2003039598A1 (fr) 2001-11-05 2002-11-05 Inhibiteurs selectif de recaptage de la norepinephrine et de la serotonine utilises dans le traitement du syndrome de la fibromyosite, de l'encephalo-myelite myalgique et de la douleur

Country Status (7)

Country Link
US (1) US6635675B2 (fr)
EP (2) EP2322225B1 (fr)
AT (1) ATE552856T1 (fr)
CA (1) CA2467356C (fr)
ES (2) ES2433080T3 (fr)
PT (2) PT1463528E (fr)
WO (1) WO2003039598A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119884A1 (en) * 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
US7619005B2 (en) * 2000-11-01 2009-11-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans with Multiple Sclerosis
WO2005000203A2 (fr) * 2001-10-31 2005-01-06 Sention, Inc. Methodes permettant de traiter la deficience cognitive et d'ameliorer la cognition
US20030232890A1 (en) * 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
US20070117869A1 (en) * 2000-11-01 2007-05-24 Cognition Pharmaceuticals Llc Methods for treating coginitive impairment and improving cognition
US20050059743A1 (en) * 2000-11-01 2005-03-17 Sention, Inc. Methods for treating mild cognitive impairment and alzheimer's disease
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
AU2003213009A1 (en) * 2002-02-12 2003-09-04 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
EP1545489A4 (fr) * 2002-07-24 2006-08-23 Cypress Bioscience Inc Traitement de la depression consecutive a la douleur
CN1674907A (zh) * 2002-08-14 2005-09-28 法玛西亚普强责任有限公司 瑞波西汀在治疗热潮红中的用途
EP1558231A4 (fr) * 2002-10-03 2010-09-08 Cypress Bioscience Inc Escalade posologique et dose quotidienne fractionnee d'antidepresseurs pour traiter des troubles neurologiques
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
KR100845932B1 (ko) * 2002-12-13 2008-07-11 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 관련 질환의 치료를 위한 프레가발린및 그의 유도체
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
ATE401872T1 (de) * 2003-02-14 2008-08-15 Pf Medicament Verwendung von dem (1s,2r)-milnacipran-enantiomer zur herstellung eines arzneimittels
EP1675582A1 (fr) * 2003-09-12 2006-07-05 Warner-Lambert Company LLC Combinaison comportant un ligand alpha-2-delta et un inhibiteur selectif du recaptage de la serotonine et/ou un inhibiteur selectif du recaptage de la noradrenaline et permettant le traitement de la depression et des troubles anxieux
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
AU2005238296A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
US20070036843A1 (en) * 2005-01-28 2007-02-15 Collegium Pharmaceutical, Inc. Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
CA2615403C (fr) 2005-07-15 2015-06-16 Amr Technology, Inc. Tetrahydrobenzazepines substituees par aryle et heteroaryle, et leur utilisation pour bloquer la reabsorption de la noradrenaline, de la dopamine, et de la serotonine
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
WO2008009663A1 (fr) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Traitement de la douleur
WO2008104957A2 (fr) * 2007-02-28 2008-09-04 Ranbaxy Laboratories Limited Nouvelles formes polymorphes d'hydrochlorure de milnacipran
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
FR2944011B1 (fr) 2009-04-03 2011-05-20 Pf Medicament Derives d'aminocyclobutane ou d'aminocyclobutene, leur procede de preparation et leur utilisation a titre de medicaments.
WO2010129689A1 (fr) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Limited Formulations de milnacipran
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
NZ596104A (en) 2009-05-12 2014-01-31 Albany Molecular Res Inc 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
CA2779711C (fr) * 2009-11-06 2016-11-01 Forest Laboratories Holding Limited Nouvelles formes cristallines du (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanecarboxamide
EP2606049A4 (fr) 2010-08-17 2014-01-08 Albany Molecular Res Inc Dérivés 2,5-méthano- et 2,5-éthano-tétrahydrobenzazépine et utilisation de ceux-ci pour bloquer le recaptage de la norépinéphrine, de la dopamine, et de la sérotonine
FR2978350B1 (fr) 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2508035A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4891223A (en) 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
FR2640972B1 (fr) 1988-12-28 1991-04-19 Pf Medicament
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
CA2041774C (fr) 1990-11-27 1994-04-19 Mircea A. Mateescu Utilisation d'amylose reticulee en tant que matrice pour la liberation lente de composes biologiquement actifs
US5603956A (en) 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
GB9215043D0 (en) 1992-07-15 1992-08-26 Flow Inc K Fluid mass flow meters
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5397574A (en) 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
US5399358A (en) 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5419917A (en) 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
WO1995022521A1 (fr) 1994-02-22 1995-08-24 Asahi Kasei Kogyo Kabushiki Kaisha Derive d'aminoalkylcyclopropane
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5399359A (en) 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
AU696855B2 (en) 1994-03-18 1998-09-17 Shire Laboratories, Inc. Emulsified drug delivery systems
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US6103263A (en) 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
EP0759299B1 (fr) * 1995-08-16 2000-04-26 Eli Lilly And Company Potentialisation de la sérotonine
FR2746314B1 (fr) 1996-03-25 1998-06-12 Pf Medicament Produit contenant du milnacipran et de l'idazoxan comme preparation pharmaceutique combinee
CA2250042A1 (fr) * 1996-03-25 1997-10-02 Eli Lilly And Company Traitement de la douleur par l'utilisation d'une combinaison synergique d'un antipsychotique atypique et un medicament utilise dans le traitement de la douleur
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
ATE314054T1 (de) 1996-10-25 2006-01-15 Shire Lab Inc Osmotisches verabreichungssystem für lösliche dosen
US5837379A (en) 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
FR2759906B1 (fr) 1997-02-21 2004-06-04 Pf Medicament Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques
CA2216215A1 (fr) 1997-04-05 1998-10-05 Isa Odidi Formulations a liberation prolongee, utilisant des polymeres intelligents, avec caracteristiques de mouillabilite opposees, correspondant a une hydrophobie et a une hydrophilie
EP0914098B1 (fr) 1997-05-30 2003-10-01 Osmotica Corp. Dispositif a osmose multicouches
US5885616A (en) 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US5916595A (en) 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
AU3891299A (en) * 1998-05-21 1999-12-06 Eli Lilly And Company Combination therapy for treatment of depression
US6106862A (en) 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US6099862A (en) 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
AU3898000A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of neuropathic pain or fibromyalgia
CA2380432A1 (fr) 1999-08-13 2001-02-22 Iredell W. Iglehart, Iii Utilisations de compositions pour le traitement ou la prevention de troubles du sommeil au moyen de doses tres faibles de cyclobenzaprine
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
EP1353675A2 (fr) * 2001-01-02 2003-10-22 PHARMACIA & UPJOHN COMPANY Nouvelles combinaisons medicamenteuses

Also Published As

Publication number Publication date
US20030139476A1 (en) 2003-07-24
ATE552856T1 (de) 2012-04-15
ES2395462T3 (es) 2013-02-12
CA2467356A1 (fr) 2003-05-15
ES2433080T3 (es) 2013-12-09
EP2322225B1 (fr) 2013-07-31
CA2467356C (fr) 2008-06-17
EP2322225A1 (fr) 2011-05-18
PT2322225E (pt) 2013-11-07
PT1463528E (pt) 2012-06-27
EP1463528A1 (fr) 2004-10-06
WO2003039598A1 (fr) 2003-05-15
US6635675B2 (en) 2003-10-21
EP1463528B1 (fr) 2012-04-11

Similar Documents

Publication Publication Date Title
WO2003039598A8 (fr) Inhibiteurs selectif de recaptage de la norepinephrine et de la serotonine utilises dans le traitement du syndrome de la fibromyosite, de l'encephalo-myelite myalgique et de la douleur
WO2004047830A3 (fr) Composition pharmaceutique contenant un agoniste beta-3-adrenorecepteur et un inhibiteur de recaptage de la serotonine et/ou de la norepinephrine
WO2003096983A3 (fr) Methode de traitement de troubles dyslipidemiques
PL372372A1 (en) Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
WO2002053140A3 (fr) Nouvelles combinaisons medicamenteuses
WO2003032914A3 (fr) Procedes de traitement de la consommation abusive de substances psychoactives a l'aide d'inhibiteurs de la cholinesterase
WO2002038142A3 (fr) Compositions serotoninergiques et methodes de traitement de la deficience cognitive legere
BR0116206A (pt) Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
BR0112292A (pt) Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
WO2001062341A3 (fr) Agents therapeutiques
WO2004062624A3 (fr) Methode pour traiter des nausees, des vomissements, des haut-le-coeur ou une association de ces symptomes
WO2004101742A3 (fr) Inhibiteurs de protease pour les coronavirus et le sars-cov et leur utilisation
WO2006098979A3 (fr) Formes posologiques d'aminopterine et methodes pour troubles inflammatoires
WO2002076388A3 (fr) Procedes permettant d'augmenter l'activite analgesique et d'attenuer les effets excitateurs indesirables d'agonistes opioides agissant de façon bimodale par inhibition du ganglioside gm1
EP0824917A3 (fr) Utilisation d'un serotonine agoniste du 5-HT1F dans la fabrication d'un médicament pour le traitement ou l'amélioration du rhume ou de la rhinite allergique
WO2003092606A3 (fr) Inhibiteurs de cholinesterase pour prevenir les blessures causees par des produits chimiques
WO2001041754A3 (fr) Inhibiteurs d'agregation plaquettaire induite par le collagene
WO2003068159A3 (fr) Compositions et methodes de traitement de la douleur a l'aide d'inhibiteurs de cyclo-oxygenase 1
WO2006057997A3 (fr) Therapies inhibitrices de la plasmine
WO2001092274A3 (fr) Inhibiteurs de la naaladase pour le traitement des affections de la retine
WO2003065970A3 (fr) Traitement de la fibromyalgie et du syndrome de fatigue associe au moyen d'antagonistes ou d'agonistes partiels de recepteurs 5ht1a
WO2003015690A3 (fr) Methode de traitement de l'insomnie primaire
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2003035046A3 (fr) Composes organiques
WO2002060533A3 (fr) Compositions medicamenteuses a faibles effets secondaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: EXCEPT/SAUF US

WWE Wipo information: entry into national phase

Ref document number: 2002793880

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2467356

Country of ref document: CA

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 20/2003 UNDER (81) ADD "US"; AS A CONSEQUENCE REPLACE "(71) APPLICANT" BY "(71) APPLICANT (FOR ALL DESIGNATED STATES EXCEPT US)" AND REPLACE "(72) INVENTORS" BY "(72) INVENTORS; AND (75) INVENTORS/ APPLICANTS (FOR US ONLY)"; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2002793880

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载